N/A N=14 Pharmacotoxicology of Trichloroethylene Metabolites
Congenital Lactic Acidosis
Primary: Hypothesize That Subject's Genotype Will Determine How DCA is Metabolized. — 1592; 232 Minutes — p=0.023
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=7 Pharmacotoxicology of Trichloroethylene Metabolites
Healthy
Primary: Plasma DCA (Microgram/ml) After 5 Days of Therapeutic Level Chloral Hydrate on Arm 2A. — 1.64 micrograms/ml
N/A N=15 Effect on Acetaminophen Metabolism by Liquid Formulations
Acetaminophen Metabolism · Acetaminophen Poisoning · Drug Metabolism by Excipients
Primary: Acetaminophen Metabolites — 2.411; 2.009 mcg.hr/ml
Phase 4 N=21 Protective Effects of Propylene Glycol in Daily Acetaminophen Dosing
Acetaminophen Toxicity
Primary: Rise in Plasma Transaminases: Proportion of Responders. — 6; 8 Participants — p=0.59
Phase 2 N=36 In Vivo Assessment of Silver Biomaterial Nano-Toxicity
Healthy
Primary: Change in Sodium Blood Levels — -0.1; 0.2 mmol/L
N/A N=274 Pathogenesis of Adverse Drug Reactions
Seizures
Primary: Drug (Valproic Acid or Carbamazepine) Metabolite Profiles in Urine — 15.2; 13.1; 1.15; 2.13 nmol per mg creatinine
Phase 1 N=38 Clinical Evaluation of the Phototoxic Potential of Xenaderm Ointment
Healthy
Primary: Skin Reaction Score — 0.4; 0.5; 0.1; 0.4 units on a scale
N/A N=312 Predicting Severe Toxicity of Targeted Therapies in Elderly Patients With Cancer
Cancer
Primary: Rate of Severe Toxicity — 14; 75; 43 Participants
Phase 4 N=19 Treatment of Adolescent Antimuscarinic (Anticholinergic) Toxidrome
Anticholinergics Toxicity
Primary: Comparison of RASS Score Between Physostigmine and Lorazepam: Before Bolus — 1.5; 1 score on a scale
Phase 1 N=24 PP100-01 (Calmangafodipir) for Overdose of Paracetamol
Paracetamol Overdose
Primary: Safety Events — 6; 6; 6; 6 participants
N/A N=19 The Adverse Drug Reaction (ADRe) Profile for Polypharmacy
Polypharmacy
Primary: Number of Participants With Changes in Signs and Symptoms Related to Adverse Effects of Prescribed Medicines. Clinical Gains and Benefits to Residents — 17 Participants
N/A N=3,939 Drug Use Investigation Of Varenicline (Regulatory Post Marketing Commitment Plan)
Smoking Cessation
Primary: Risk Factors for the Frequency of Treatment Related Adverse Events - Gender. — 377; 336 participants — p=<0.001
Phase 2 N=12 In-Vivo Assessment of Silver Biomaterial Nano-Toxicity 32 Ppm
Healthy
Primary: Change Sodium Blood Levels — 141.8; 141.2 mmol/L
N/A N=11,157 Tolterodine Drug Use Investigation.(Post Marketing Commitment Plan)
Overactive Bladder
Primary: Confirmation of the Incidence of All Treatment Related Adverse Events (TRAEs). — 984 participants
Phase 2 N=300 Clinical Trial of Two Study Drinks in Detoxification of Environmental Toxicants and Carcinogens
Healthy
Primary: Carcinogen Detoxification of Metabolites in Urine. — 7.26; 6.11; 3052.39; 1843.29 ng/mL
N/A N=2,272 Drug Use Investigation of Jzoloft.
Panic Disorder · Depression
Primary: Number of Participants of Treatment Related Adverse Events (TRAEs) — 263 participants
Phase 2 N=24 Phase II Study of Digitoxin to Treat Cystic Fibrosis
Cystic Fibrosis
Primary: Effect of Digitoxin on IL-8 (Interleukin 8) in Induced Sputum in Stable Cystic Fibrosis (CF) Patients. — 4.59; 4.96; 5.04; 4.94 log 10 (pg/mL) — p=>0.05
N/A N=451 Special Investigation For Patients With Renal And/Or Hepatic Disorders On Aromasin
Breast Neoplasms
Primary: Number of Participants With Factors Considered to Affect the Safety and/or Efficacy of Exemestane — 126; 324; 372; 68 participants
N/A N=5,060 Drug-Targeted Alerts for Acute Kidney Injury
Acute Kidney Injury
Primary: Percentage of Patients With Progression of AKI OR Dialysis OR Death — 639; 585 Participants
Phase 1 N=30 Pharmacokinetics of Doxorubicin in cTACE of Liver Cancer
Liver Cancer
Primary: Pharmacokinetics Profile-- Peak of Plasma Concentration (Dose-normalized) — 2.67; 3.68; 7.11; 0.08 ng/mL/mg — p=.036
Phase 2 N=26 Relative Mitochondrial Toxicity of Tenofovir Alafenamide (TAF) vs. Tenofovir Disoproxil Fumarate (TDF)
HIV/AIDS · Antiviral Toxicity · Antiviral Drug Adverse Reaction
Primary: Change in Mitochondrial Function [Cellular Oxygen Consumption (COC)] Over 12 Months After Switch of Antiretrovirals. — 50; 70 pmoles O2/min — p=<0.001
N/A N=7,740 Drug Use Investigation for Humira® - All Patient Investigation for Rheumatoid Arthritis
Rheumatoid Arthritis
Primary: Total Number of Patients With Adverse Events — 27.8 Percentage of Patients
N/A N=204 Safety & Prevention Outcomes Study
Drug Overdose · Opioid-Related Disorders
Primary: Overdose Risk Behavior — -1.54; -0.51 Scores on a scale
Phase 2 N=9 Safety and Toxicity Study of Sorafenib in Patients With Kidney Cancer
Carcinoma, Renal Cell · Kidney Disease · Kidney Cancer
Primary: Time-to-progression (TTP) — 5.3 months
Phase 2 N=25 Phase 2 Study of Atorvastatin Safety and Antitumor Effects in Non-Hodgkin's Lymphoma
Leukemia · Lymphoma, Non-Hodgkin
Primary: Tumor Apoptosis — 7 Participants
N/A N=31 Methadone Monitoring for Insights Into Adverse Events
Pain · Opiate Addiction
Primary: Total Methadone Peak Plasma Concentration — 107.3; 315.4; 362.2 ng/mL
Phase 4 N=27 Acetaminophen Adduct Formation in Non-Drinkers Taking Therapeutic Doses of Acetaminophen for Ten Consecutive Days
Drug Induced Liver Injury
Primary: Serum Level of Acetaminophen-cysteine (APAP-Cys) Protein Adducts — 0.0; 0.3; 0.3; 0.4 nmol/mL
Phase 4 N=276 Aminotransferase Trends During Prolonged Acetaminophen Dosing
Drug Toxicity · Healthy
Primary: The Proportion of Subjects Treated With Long-term Acetaminophen (4 g/Day) That Develops Persistent ALT Elevations. — 204; 47; 1; 0 participants
N/A N=396 Achieving Medication Safety During Acute Kidney Injury
Kidney Failure, Acute
Primary: Adverse Drug Events or Potential Adverse Drug Events — 99; 104 Patient-Medication Pairs
N/A N=2,492 Drug Use Investigation for Toviaz
Overactive Bladder (OAB)
Primary: Number of Participants With Treatment-Related Adverse Events — 415 Participants